Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 3:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 4,118 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Experimental 2 Clear all

Conditions: Meningococcal Immunisation, Healthy Volunteers
Interventions: Pentavalent Meningococcal ABCYW vaccine, MenACYW conjugate vaccine, Meningococcal group B vaccine, Placebo, MenABCYW conjugate vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 10 Years to 25 Years
Enrollment: 1,215 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 46
States / cities: Birmingham, Alabama • Guntersville, Alabama • Tempe, Arizona + 36 more

Conditions: Gastroparesis
Interventions: Domperidone; Drug
Lead sponsor: Arnold, George, M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cancer, Cancer Pain, Chronic Cancer Pain
Interventions: VR-CAN prototype chronic cancer pain therapy -- virtual reality program delivering CBT for chronic cancer pain management, Active Control -- two-dimensional tablet-delivered intervention; Device
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Durham, North Carolina

Conditions: Alcohol and Substance-Related Mental Disorders
Interventions: SBIRT, Treatment as usual; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 15 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Sickle Cell Disease, Pulmonary Hypertension
Interventions: Hydroxyurea; Drug
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 10 Years to 25 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer
Interventions: Tucatinib, Doxil; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Columbia, Maryland • Bensalem, Pennsylvania • Nashville, Tennessee + 4 more

Conditions: Major Depressive Disorder
Interventions: ONO-2333Ms Experimental 2, Placebo, ONO-2333Ms Experimental 1; Drug
Lead sponsor: Ono Pharma USA Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Volunteers
Interventions: Volunteering; Behavioral
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Non-small Cell Lung Cancer
Interventions: Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed, HER3-DXd; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 5
States / cities: Lexington, Kentucky • Baltimore, Maryland • Fargo, North Dakota + 2 more

Conditions: Health Behavior
Interventions: LifePak Nano; Dietary Supplement
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Vaping
Interventions: Exposure to Influencer Age and Context Variations in E-Cigarette Marketing; Other
Lead sponsor: University of Southern California; Other
Eligibility: 14 Years to 17 Years
Enrollment: 6,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Botulism
Interventions: rBV A/B; Biological
Lead sponsor: California Department of Public Health; Other
Eligibility: 18 Years to 69 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Richmond, California • West Jefferson, Ohio

Conditions: Diabetes Mellitus, Type 2
Interventions: Nutritional Formula, Usual diet, Diabetes Meal Plan with experimental diabetes-specific nutritional shake, diabetes specific cereal, and diabetes specific snack bars.; Other
Lead sponsor: Abbott Nutrition; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Bloomington, Indiana • Cincinnati, Ohio

Conditions: Asthma
Interventions: Anti-Asthma Herbal Medical Intervention (ASHMI); Drug
Lead sponsor: Xiu-Min Li; Other
Eligibility: 18 Years to 55 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Peyronie Disease, Sexual Dysfunction, Physiological, Sexual Dysfunction Male, Genital Diseases, Male
Interventions: Autologous Platelet-Rich Plasma (PRP), Placebo (Normal Saline); Biological · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: COVID-19
Interventions: VIR-7831, Placebo, Remdesivir; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 74
States / cities: Tucson, Arizona • Fresno, California • Loma Linda, California + 50 more

Conditions: Nutrition Intervention, Healthy Eating, Diet, Healthy, Hunger, Food Security
Interventions: Nutrition Secure Indianapolis Food Box Intervention, Nutrition Secure Indianapolis Nutrition Education; Other · Behavioral
Lead sponsor: Purdue University; Other
Eligibility: 5 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: Healthy
Interventions: Serum Total Protein Measurement with TS Meter-DSP and Refractix DSP; Device
Lead sponsor: Reichert, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Lauderhill, Florida

Conditions: GVHD, Hematologic Neoplasms
Interventions: Cyclophosphamide, abatacept, Methotrexate, Tacrolimus; Drug
Lead sponsor: Dimitrios Tzachanis, MD PhD; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Blood Pressure, Diabetes, Obesity, Insulin Resistance, Diuretics Drug Reactions, Sympathetic Nerve Activity
Interventions: Hydrochlorothiazide 12.5Mg Tab, Clonidine Pill, Placebo; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 79 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Influenza
Interventions: Favipiravir, Placebo comparator; Drug
Lead sponsor: MDVI, LLC; Industry
Eligibility: 20 Years to 80 Years
Enrollment: 530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 148
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 118 more

Conditions: Healthy
Interventions: LY3074828, Pre-filled syringe (PFS), Autoinjector (AI); Drug · Device
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Healthy
Interventions: Light emitting glasses; Device
Lead sponsor: Michigan State University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: East Lansing, Michigan

Conditions: Multiple Sclerosis
Interventions: PromPT-MS; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Search by objective public record fields.

Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents

Domperidone for Refractory Gastrointestinal Disorders

Cognitive Behavioral Theory-assisted Virtual Reality for Chronic CANcer Pain (VR-CAN)

Effectiveness of an Evidence-based Stepped Care System for Alcohol and Other Drug Use Problems Among Congolese Refugees in Zambia

Hydroxyurea for Children and Young Adults With Sickle Cell Disease and Pulmonary Hypertension

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Placebo-Controlled Study of ONO-2333Ms in Patients With Recurrent Major Depressive Disorder

Take 2 Pills and Go Volunteer in the Morning

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

Evaluation of Changes in Skin Carotenoid Scores in Medical Students Following a Dietary Supplement-based Intervention

E-cigarette Social Media Marketing and Its Perceptions by Youth

Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid

Effects of Nutritional Products on Blood Glucose in Subjects With Type 2 Diabetes

Safety Study of Chinese Herbal Therapy to Treat Asthma

PRP for Treatment of Peyronie's Disease

VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Improving Dietary Quality Through Animal Source Protein Accessibility in a Low-Resource Setting

Refractix DSP and TS Meter-DSP Measurement Comparison

Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation

Mitigating the Pro-inflammatory Phenotype of Obesity

Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza

A Study of Injections of LY3074828 in Healthy Participants

The Impact of Light Exposure on Cognitive Function in Classrooms

Promotion of Exercise Through Physical Therapy for Multiple Sclerosis: A Pilot Study